Boston Scientific CORP 8-K filings

Boston Scientific has approved its 2025 annual bonus plan and two performance share programs for executive officers, focusing on company-wide performance and shareholder value.

Boston Scientific has finalized its acquisition of Axonics, Inc., a medical technology company specializing in devices for urinary and bowel dysfunction, for $3.7 billion.

Boston Scientific has announced the resumption of its AVANT GUARD clinical trial, which studies a new population of drug-naive patients with persistent atrial fibrillation.

Boston Scientific reported robust third-quarter 2024 results, surpassing revenue guidance and achieving significant growth across its cardiovascular segment.

Boston Scientific has appointed David Habiger to its board of directors, increasing the board size to eleven members, effective July 30, 2024.

Boston Scientific reported strong second-quarter 2024 results, exceeding sales and adjusted EPS guidance, driven by robust growth across all segments and regions.

Boston Scientific Corporation has appointed Dr. Cheryl Pegus to its board of directors and amended its revolving credit agreement, extending the maturity date and adjusting financial terms.

Boston Scientific Corporation's stockholders approved amendments to the company's bylaws at the 2024 Annual Meeting, including updates for advance notice and universal proxy rules.

Boston Scientific exceeded expectations in the first quarter of 2024, reporting significant growth in sales and earnings per share.

Boston Scientific's acquisition of Axonics is delayed due to a second request for information from the Federal Trade Commission, pushing the expected completion to the second half of 2024.

Boston Scientific's finance subsidiary has successfully priced a $2 billion offering of senior notes to help fund the acquisition of Axonics, Inc.

Boston Scientific has appointed Jonathan Monson as Senior Vice President, Investor Relations and Emily Woodworth as Senior Vice President, Global Controller and Chief Accounting Officer, both effective March 1, 2024.

Boston Scientific exceeded its own guidance with a strong fourth quarter and full year 2023, driven by robust sales growth and increased profitability.